平方毫米
调节器
抑制器
转录因子
生物
药物发现
计算生物学
基因
临床试验
突变体
药品
P53蛋白
癌症研究
生物信息学
医学
药理学
遗传学
作者
Kian Hoe Khoo,Chandra Shekhar Verma,David Philip Lane
摘要
The tumour suppressor p53 is the most frequently mutated gene in human cancer, with more than half of all human tumours carrying mutations in this particular gene. Intense efforts to develop drugs that could activate or restore the p53 pathway have now reached clinical trials. The first clinical results with inhibitors of MDM2, a negative regulator of p53, have shown efficacy but hint at on-target toxicities. Here, we describe the current state of the development of p53 pathway modulators and new pathway targets that have emerged. The challenge of targeting protein-protein interactions and a fragile mutant transcription factor has stimulated many exciting new approaches to drug discovery.
科研通智能强力驱动
Strongly Powered by AbleSci AI